PLUS THERAPEUTICS, Inc. (PSTV) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Final remarks, so after Q&A, just turn it back to me for a few seconds, please. Good afternoon, ladies and gentlemen. Welcome to PLUS Therapeutics' fourth quarter and full year 2024 results conference call. Before we begin, we want to advise you that over the course of the call, including any question and answer session, forward-looking statements will be made regarding events, trends, business prospects, and financial performance, which may affect PLUS Therapeutics' future operating results and financial position. All such statements are subject to risk and uncertainties, including the risk and uncertainties described under the risk factors section included in PLUS Therapeutics' annual report on Form 10-K and quarterly reports on Form 10-Q, filed with the Securities and Exchange Commission from time to time. Plus Therapeutics advises you to review these risk factors in considering such statements. Plus Therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made. It is now my pleasure to turn the floor over to Dr. Mark Hedrick, Plus Therapeutics President and Chief Executive Officer. Sir, you may begin. Thank you, Sherry. Good afternoon, everyone. Thank you once again for taking the time to join us today as we provide an overview of recent business highlights and discuss our fourth quarter and full year 2024 financial results and go-forward guidance. Joining me for the call today is Mr. Andrew Sims, our Chief Financial Officer. I'll begin the call by providing more detail on four important recent corporate announcements. Then I'll discuss progress in our most advanced clinical programs, and then discuss progress and plans for C-INSIDE and its commercialization. Afte...